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Background: An increased breast cancer incidence and poor survival have been reported for women with neurofibromatosis 1 (NF1).
To explain the poor survival, we aimed to link the histopathology and clinical characteristics of NF1-associated breast cancers.
Methods: The Finnish Cancer Registry and the Finnish NF Registry were cross-referenced to identify the NF1 patients with breast
cancer. Archival NF1 breast cancer specimens were retrieved for histopathological typing and compared with matched controls.
Results: A total of 32 breast cancers were diagnosed in 1404 NF1 patients during the follow-up. Women with NF1 had an
estimated lifetime risk of 18.0% for breast cancer, and this is nearly two-fold compared with that of the general Finnish female
population (9.74%). The 26 successfully retrieved archival NF1 breast tumours were more often associated with unfavourable
prognostic factors, such as oestrogen and progesterone receptor negativity and HER2 amplification. However, survival was worse
in the NF1 group (P¼ 0.053) even when compared with the control group matched for age, diagnosis year, gender and oestrogen
receptor status. Scrutiny of The Cancer Genome Atlas data set showed that NF1 mutations and deletions were associated with
similar characteristics in the breast cancers of the general population.
Conclusions: These results emphasise the role of the NF1 gene in the pathogenesis of breast cancer and a need for active follow-
up for breast cancer in women with NF1.
Neurofibromatosis type 1 (NF1) is an autosomal dominant cancer
syndrome with a birth incidence as high as 1 : 2000 (Huson et al, 1989;
Uusitalo et al, 2015). The most common features are cafe´ au lait
pigment macules, skinfold freckles and cutaneous as well as plexiform
neurofibromas (Riccardi and Eichner, 1986). Epidemiologic studies
have reported a 2.7 to 5 times higher risk for cancer in NF1 compared
with the general population (Sørensen et al, 1986; Zo¨ller et al, 1997;
Walker et al, 2006; Seminog and Goldacre, 2013; Uusitalo et al, 2016).
Tumours typical in NF1 include intracranial gliomas and malignant
peripheral nerve sheath tumours (MPNST). In addition to neoplasms
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originating from the nervous system, other aggressive tumours, such
as gastrointestinal stromal tumours (GIST) and pheochromocytomas,
are related to NF1 (Walther et al, 1999; Maertens et al, 2006; Uusitalo
et al, 2016). The cancer survival of NF1 patients has also been
reported to be inferior to that of cancer patients without NF1
syndrome (Uusitalo et al, 2016).
There are numerous case reports on NF1 and breast cancer, but
less than half a dozen reports containing data that allow
generalisation of the results (Sharif et al, 2007; Madanikia et al,
2012; Wang et al, 2012; Seminog and Goldacre, 2015). The data
suggest an increased incidence for breast cancer in NF1. We have
recently published a population-based study that showed beyond
doubt an elevated risk for breast cancer in NF1 (Uusitalo et al,
2016). In the study by Uusitalo et al (2016), 21.8% of all observed
cancer events in female NF1 patients were breast cancers.
In particular, female NF1 patients under the age of 40 years have
breast cancer incidence that is 410 times that of the general
Finnish population (Uusitalo et al, 2016). The NF1 patients also
have elevated breast cancer mortality and poor breast cancer
survival (Evans et al, 2011; Uusitalo et al, 2016).
The NF1 syndrome is caused by mutations in the NF1 gene that
encodes neurofibromin, the main function of which is to facilitate
the conversion of active Ras-GTP to inactive Ras-GDP (Xu et al,
1990; Scheffzek et al, 1997). Comparative oncogenomics implicates
the NF1 as a driver gene in breast cancer (Wallace et al, 2012).
Every fourth breast cancer case in The Cancer Genome Atlas
(TCGA) data set was reported to harbour a deletion or mutation in
the NF1 gene (Wallace et al, 2012). The NF1 mutations and
deletions are even more prevalent in HER2 (human epidermal
growth factor receptor 2) -amplified and basal tumour subtypes of
breast cancer.
Breast cancer is a heterogeneous group of tumours with a
variable prognosis. The most important prognostic factors are
tumour grade, tumour size, regional lymph nodes status,
proliferation index, oestrogen receptor (ER) and progesterone
receptor (PR) status and amplification of the HER2 gene (Finek
et al, 2007). The same factors are used as predictive for the
treatment of individual patients with breast cancer (Coates et al,
2015). The intrinsic breast cancer subtypes have been established
based on gene expression profiles (Perou et al, 2000). At the
molecular level, breast cancers may be classified into luminal A,
luminal B, HER2-amplified and triple-negative or basal-like
cancers. Luminal A and B are both ER/PR-positive types, but
luminal B may also display HER2 amplification and high Ki-67
expression. The HER2 subtype is negative for ER and PR and
shows HER2 amplification. Triple-negative (ER , PR and
HER2 ) breast cancers form an aggressive subtype and a part of
these tumours, the basal-like type, express cytokeratins of the basal
epithelial layer, such as cytokeratin 5/6 (CK5/6) and cytokeratin 14
(CK14; Coates et al, 2015).
The current study was designed to elucidate the biological and
clinical features associated with the poor survival of NF1-associated
breast cancer in terms of histopathology and clinical characteristics.
MATERIALS AND METHODS
Patients. The study adhered to the Declaration of Helsinki
principles and was approved by the Ethics Committee of the
Southwest Finland Hospital District, Finland’s Ministry of Social
Affairs and Health and the National Supervisory Authority for
Welfare and Health (Valvira). A research permit was obtained
from each participating hospital.
The Finnish NF Registry is population-based and has been
previously described in detail (Uusitalo et al, 2015, 2016). The NF1
cohort of the current study comprises 1404 NF1 patients (20 248
person-years of follow-up) from the 5 university and 15 central
hospitals in Finland. The NF1 patients were followed up for breast
cancer starting from the date of the first hospital visit due to NF1
between 1987 and 2011 and ending at death, emigration or 31
December 2013, whichever occurred first. Of the 1404 patients,
737 were female and 667 male. The NF1 cohort was cross-
referenced with the Finnish Cancer Registry (http://www.cancer.fi/
syoparekisteri/en/) to find all NF1 patients with a breast cancer
diagnosis. Follow-up information on life status and emigration of
the patients was obtained from the Cause of Death Registry and
Population Register Centre. The Cancer Registry search revealed
49 breast cancers diagnosed in 45 females and 1 male with NF1.
Two of the female and the male patient had two primary breast
cancers. Out of the 49, a total of 32 breast cancers had been
diagnosed in the NF1 cohort during follow-up.
Tumour samples. Archival surgery specimens of the available
NF1 female breast tumours and clinical information related to
the samples (including tumour size and the lymph node status at
the time of surgery) were retrieved from the pathology units of the
participating hospitals. Search was restricted to invasive breast
carcinomas, and only one breast cancer was included in the case of
two separate breast cancer diagnoses. Formalin-fixed, paraffin-
embedded breast cancer tissue samples from 26 NF1 breast cancer
patients diagnosed in 1992–2011 were available for analysis.
Histology, immunohistochemistry and in situ hybridisation.
Sections, 3mm thick, were cut from the formalin-fixed, paraffin-
embedded breast cancer tissue samples and stained with
haematoxylin and eosin (HE) for histological analysis. The HE-
stained breast tumour slides were reviewed for histological type
and grade of each tumour according to the WHO classification of
tumours of the breast (Lakhani et al, 2012). The TNM classification
of malignant tumours was used to grade the extent of spread of the
breast carcinomas (Lakhani et al, 2012).
Immunolabelling for ER, PR, Ki-67, CK5/6, CK14 and HER2
was performed using a BenchMark XT automated immunostaining
instrument (Roche/Ventana, Tucson, AZ, USA) and ultraView
Universal DAB Detection Kit. Sections for HER2 amplification
testing were selected on the basis of immunohistochemistry, and
gene amplification was thereafter confirmed with in situ hybridisa-
tion (Coates et al, 2015). The HER2/Chr17 double in situ
hybridisation was performed with the BenchMark XT using the
Ventana HER2 DNA probe, Inform Chromosome 17 probe,
ultraView SISH detection kit to detect HER2 and the ultraView
Alkaline Phosphatase Red ISH Detection Kit to detect Chr17.
All reagents were from Roche/Ventana. The ISH Protease 3 for
8min was used as a pretreatment step, and HER2 hybridisation
was performed at 52 1C for 6 h and Chr17 hybridisation at 44 1C
for 2 h. The cutoff for ER and PR positivity was nuclear
immunoreactivity in 410% of tumour cells.
The breast cancers were classified into subgroups following
these recommendations (Coates et al, 2015):
 ‘Luminal A’¼ER/PRþ , HER2 , Ki-67 o14%
 ‘Luminal B’¼ (1) ERþ , HER2þ or (2) ERþ , HER2 ,
and either Ki-67 414% or PR
 ‘HER2 subtype’¼ ER , PR , HER2þ
 ‘Triple-negative’¼ER , PR , HER2
 ‘Basal-like’¼ER , PR , HER2 , CK5þ .
Case–control analysis of tumour characteristics. A case–control
analysis for tumour type and grade was used to study the
characteristics of the 26 NF1 breast cancer cases. For each NF1
breast cancer, five age- and sex-matched controls without NF1
were randomly sampled from the data of Auria Biobank, Turku,
Finland (https://www.auriabiopankki.fi/?lang=en). Auria Biobank
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hosts archived diagnostic specimens obtained from patients
attending the Turku University Hospital for diagnosis and
treatment of conditions requiring biological cell or tissue speci-
mens. The catchment population isB500 000 people. The biobank
retrieves clinical information associated with the samples from the
hospital electronic health records. The control breast cancer
samples had been analysed in the same clinical laboratory and
using practically the same methods as the NF1 samples.
The clinical and tissue-based tumour parameters were com-
pared between the NF1 group and the control group. The tissue-
based parameters included histological grade, size of the primary
tumour (pT), number of metastatic lymph nodes (pN), Ki-67
positivity, presence of ER- and PR-positive cancer cells and HER2
amplification.
NF1 alterations in breast cancers of the general population. In
order to evaluate the occurrence and relevance of alterations in the
NF1 gene in breast cancers of the general population, we used data
generated by the TCGA Research Network (http://cancergenome.-
nih.gov/; accessed 7 October 2016). This database contains somatic
mutations and copy number alterations detected in tumours
together with several clinical characteristics of the cancers and
patients. Invasive breast carcinomas included in the TCGA data set
were classified by NF1 status. Samples with normal NF1 were
compared with those that harboured a mutation or some level of
deletion in NF1.
Statistical methods and survival. Follow-up for cancer through
the population-based country-wide Finnish Cancer Registry was
done automatically using the personal identity code as a key.
Standardised incidence ratios (SIRs) of breast cancer were
calculated as the ratios of observed to expected cases, where the
expected cases were obtained by multiplying the number of
person-years with the corresponding population rate stratified by
age group, calendar period and gender. The 95% confidence
intervals (CIs) were based on the assumption that the number of
observed cases followed the Poisson distribution. The cumulative
lifetime risk (risk by the age of 85 years) and age group-specific risk
(the probability of developing breast cancer at given age range for
those alive and not diagnosed with breast cancer before) for breast
cancer was estimated by applying the method of competing risks
(mortality) with allowance for delayed entry.
Tumour characteristics coded either as binary or ordinal
variables were analysed using generalised linear mixed effects
models (GLMM; Demidenko, 2013). The grouping variable (NF1
or control) was the main exposure variable of interest. In order to
compare NF1 patients and controls matched for age and sex, the
grouping variable that indexed matched sets was included as a
random effect in the GLMM. The 5-year breast cancer survival was
studied with a five-fold randomly chosen control group without
NF1. The controls were also retrieved from Auria Biobank and
they were matched with the NF1 study group for age, breast cancer
diagnosis year, gender and oestrogen receptor status (þ / ). The
patients were followed from the time of breast cancer surgery to
death or to the end of the follow-up (31 December 2013).
Cumulative survival proportions were estimated using the Kaplan–
Meier method, and the NF1 and control groups were compared
using matched Cox’s regression model. The data satisfied the
proportional hazards assumption of Cox’s regression.
The TCGA breast cancers with a normal or mutated/deleted
NF1 were compared using the w2 test for tumour characteristics
and the Cox proportional hazards model for survival outcome
analysis.
All statistical analyses were conducted using the statistical
software R versions 3.2.2–3.3.0 (The R Foundation; https://www.r-
project.org/) with lme4 (version 1.1-11), ordinal (version 2015.6-28),
popEpi (version 0.2.1) and survival (version 2.38-3) packages.
RESULTS
NF1 patients with breast cancer. Cross-referencing the popula-
tion-based Finnish NF Registry (Uusitalo et al, 2015, 2016) with
the Finnish Cancer Registry resulted in a total of 49 breast cancers
diagnosed in 45 females and 1 male with NF1. Two of the female
patients and the male patient had two primary breast cancers
diagnosed 8.3–19.6 years apart. The youngest NF1 patient was 28
and the oldest was 84 years old at the time of diagnosis (median 49
years). A total of 31 breast cancers were diagnosed in NF1 females
and 1 in NF1 male during the follow-up period.
In reference to the known risk factors for breast cancer, 14 out
of the 45 NF1 women (31%) were nulliparous, whereas 24 (53%)
patients had had at least one birth before age 30 years. The
respective numbers among NF1 women without breast cancer were
38% and 52% (P¼ 0.458 and P¼ 0.951, respectively). The BRCA1/
2mutations were not systematically tested, but in the three patients
where this had been done, no BRCA1/2 mutations were detected;
this included the one NF1 male with breast cancer. Ovarian cancer
was not detected in any of the NF1 patients with breast cancer.
Risk for breast cancer in NF1 women. The SIR of breast cancer
was calculated using data from the Finnish Cancer Registry. A total
of 31 breast cancers were observed in the female NF1 cohort
during the follow-up, yielding a SIR of 2.82 (Table 1). The SIR for
breast cancer was highest in the youngest age groups: for women
o40 years it was 14.25, whereas in women aged 40–50 years it was
2.60. The SIR of breast cancer was not significantly increased in the
age groups of 450 years.
The cumulative risk for breast cancer in NF1 women by age of
40 years was 4.7% (95% CI 1.6–7.6%) and by age 50 years 7.8%
(95% CI 3.9–11.5%). The respective numbers in the Finnish
population are 0.45% and 2.1%. The estimated lifetime risk for
breast cancer in NF1 women was 18.0% (95% CI 11.4–24.1%)
compared with 9.7% in the general population. Women with NF1
had a 4.7% (95% CI 1.5–7.9%) risk of being diagnosed with breast
cancer during 30–39 years of age, whereas the corresponding risk
of the general population is only 0.34% (Table 2).
Histopathology, subtypes and clinical characteristics of NF1
breast cancer. Archival breast cancer tissue specimens were
obtained from 26 invasive breast cancers of female NF1 patients
who were 29 to 84 years old at the time of the breast cancer surgery
(median age 53 years). Of the breast tumours, 88.5% were ductal
carcinomas and 7.7% lobular carcinomas. The breast cancer
tumours were profiled using immunolabelling for ER, PR, Ki-67,
CK5/6 and CK14, and in situ hybridisation for HER2. The breast
cancer subtype was luminal A in 15.4% of the NF1 samples,
luminal B in 34.6%, HER2 amplified in 30.8% and triple-negative
in 19.2%. The basal-like phenotype was seen in 15.4%. The
subtypes and immunohistochemistry of NF1 breast cancer speci-
mens are shown in Table 3 by age groups. The results showed that
the HER2-amplified subtype was the most common in the age
group of o40 years (3 out of 6). In the age group of 40–50 years,
Table 1. Standardised incidence ratio (SIR) for NF1 female
breast cancer by age group
Age group Observed Expected SIR 95% CI P-value
o40 Years 9 0.63 14.25 6.51–27.04 o0.001
40–49 Years 6 2.31 2.60 0.95–5.65 0.0359
50–59 Years 8 3.75 2.13 0.92–4.20 0.0532
X60 years 8 4.30 1.86 0.80–3.66 0.1231
Total 31 11.00 2.82 1.92–4.00 o0.001
Abbreviations: CI¼ confidence interval; NF1¼ neurofibromatosis 1.
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the luminal B type was the most frequent (4 out of 6), whereas in
the age group of 450 years, the different types were more evenly
represented. Grade III was the most frequent grade in both the
youngest and the oldest age groups.
Comparison of breast cancer characteristics between NF1 and
controls. The breast cancer characteristics were compared
between the NF1 patients and matched controls (Table 4).
The results showed that the NF1 breast cancers were more often
ER negative (53.8% vs 20.9%, P¼ 0.001) and PR negative (65.4% vs
21.7%, Po 0.001). The HER2 amplification was overrepresented in
the NF1 group (30.8% vs 9.6%, P¼ 0.006). The NF1 breast cancers
were larger in size (P¼ 0.019) by TNM classification and of higher
grade (P¼ 0.050; Table 4).
Survival. Out of the 26 NF1 patients, 11 (42.3%) died during the
follow-up. Survival was similar in the cases where tissue samples could
not be retrieved (data not shown). Because the NF1 breast cancers
were more often ER negative, survival analysis was carried out using a
control group matched for age, breast cancer diagnosis year, gender
and ER status. The overall survival was worse in the NF1 group: 5-
year survival was 68.1% (95% CI 52.0–89.1%) in the NF1 group and
82.0% (95% CI 75.5–88.9%) in the control group (P¼ 0.053). This
yielded a hazard ratio of 2.34 (95% CI 0.99–5.6; Figure 1).
Relevance of NF1 alterations in breast cancers of the general
population. Mutations or deletions of the NF1 gene were observed
in 33% of the TCGA breast cancers. Patients with an NF1 deletion
or mutation in the tumour were slightly younger than those with
an intact NF1 (56.8 vs 59.2 years, P¼ 0.013). The NF1 mutations
and deletions were associated with decreased survival: 5-year
survival was 86.5% (95% CI 81.7–91.6%) for the breast cancer
patients with a normal NF1 gene status, but only 77.1% (95% CI
70.5–84.3%) for those with an NF1 mutation or deletion (hazard
ratio 1.85, 95% CI 1.14–3.00, P¼ 0.014). Comparisons of the
receptor status showed a pattern similar to the one of NF1 patients:
cancers with an NF1 mutation or deletion were significantly more
often ER and PR negative and HER2 amplified than cancers with a
normal NF1 gene (Po0.001 for all). Restricting the analysis to NF1
mutations only resulted in a similar trend in survival (hazard ratio
3.2, 95% CI 1.1–9.0, P¼ 0.031) and receptor status. However, the
differences in ER and HER2 status were not significant (P¼ 0.223
and P¼ 0.196, respectively) because of the low number of tumours
(n¼ 26) in the TCGA data set harbouring NF1 mutation.
DISCUSSION
The main findings of this study are that NF1 breast cancers are
often associated with poor survival and unfavourable prognostic
factors, such as ER and PR negativity and HER2 amplification. The
study also shows, however, that the poor prognosis of the NF1-
related breast cancer is not explained by histopathological subtype
only.
The study utilised two comprehensive population-based regis-
ters: the Finnish Neurofibromatosis Registry (Uusitalo et al, 2015,
2016) and the Finnish Cancer Registry. It is reasonable to assume
that all Finnish NF1 patients who have had breast cancer during
the follow-up are included. Our results show that the breast cancer
incidence in NF1 women aged o40 years is increased with a
cumulative risk of 4.7%. This is 10-fold compared with the control
population (0.45%), and corroborates our previous findings that
young patients with NF1 have a high SIR for breast cancer
(Uusitalo et al, 2016). Yet, half of the NF1 breast cancers were
diagnosed in women over 50 years where the incidence is
moderately increased compared with the general population.
We were not able to retrieve information on all common breast
cancer risk factors for our patients, but we do not assume that our
Table 2. The risk of breast cancer in different age groups
NF1 women Finnish women
Age group Risk (%) 95% CI Risk (%)
20–29 0.55 0.00–1.62 0.03
30–39 4.74 1.48–7.89 0.34
40–49 3.92 0.77–6.96 1.50
50–59a 5.89 1.86–9.76 2.64
60–69a 4.18 0.09–8.11 2.88
70–79 3.99 0.00–9.26 2.44
Abbreviations: CI¼ confidence interval; NF1¼ neurofibromatosis 1.
aWomen aged 50–69 years are routinely invited to mammography screening in Finland.
Table 3. Subtype/immunohistochemistry of 26 archival NF1 breast cancer tissue samples by age group
All patients Age o40 Age 40–50 Age 450
Patient age
n (%/all) n (%/age group) n (%/age group) n (%/age group)






Luminal A 4 (15.4%) 0 1 (16.7%) 3 (21.4%)
Luminal B 9 (34.6%) 2 (33.3%) 4 (66.7%) 3 (21.4%)
HER2 subtype 8 (30.8%) 3 (50.0%) 1 (16.7%) 4 (28.6%)
Basal-like 4 (15.4%) 1 (16.7%) 0 3 (21.4%)
Triple-negative, other than basal-like 1 (3.8%) 0 0 1 (7.1%)
Ki-67
o20% 9 (34.6%) 1 (16.7%) 3 (50.0%) 5 (35.7%)
420% 17 (65.4%) 5 (83.3%) 3 (50.0%) 9 (64.3%)
Grade
I 1 (3.8%) 0 0 1 (7.1%)
II 11 (42.3%) 2 (33.3%) 4 (66.7%) 5 (35.7%)
III 14 (53.8%) 4 (66.7%) 2 (33.3%) 8 (57.1%)
Abbreviations: HER2¼ human epidermal growth factor receptor 2; NF1¼neurofibromatosis 1.
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findings are because of general risk factors, such as overweight,
nulliparity, alcohol or smoking. For example, 53% of the patients
had given birth at least once by age 30 years, and parity is
associated with a decreased risk for breast cancer (Hsieh et al, 1994;
Rosner et al, 1994; Kobayashi et al, 2012). Our conclusion is that
NF1 patients share a common cancer risk factor that is a mutation
in the NF1 tumour suppressor gene. Thus, the accumulation of a
sufficient number of mutations required for malignancy may occur
earlier in NF1 syndrome.
The NF1 gene aberrations are also frequent in breast cancers in
patients who do not have the NF1 syndrome and the NF1 gene
might be a general driver in breast cancer (Wallace et al, 2012).
Wallace et al (2012) reported NF1 alterations especially in HER2-
enriched and basal subtypes where over 40% of the tumours
harboured NF1 mutations or deletions. The number of cases
included in the TCGA data set has since increased, and our
analysis of the TCGA data set, with the NF1 gene as the starting
point, shows that NF1 mutations and deletions are associated with
similar characteristics in terms of breast cancer receptor status and
survival in the general population as those in NF1 patients. Of the
TCGA breast tumours with NF1 deletion, 85% also harboured
deletion of BRCA1 that is located on the same chromosome as
Table 4. Comparison of NF1 and control breast cancers by grade, pT class, lymph node and receptor statuses and the
proliferative index Ki-67
NF1 group, n (%)a Control group, n (%)a OR (95% CI)b P-value
Total 26 130
Tumour grade
I 1 (3.8%) 21 (18.4%) 2.37 (1.00–5.61) P¼0.050
II 11 (42.3%) 49 (43.0%)
III 14 (53.8%) 44 (38.6%)
Unknown 0 16
pT class
1 11 (42.3%) 78 (66.1%) 2.87 (1.19–6.90) P¼0.019
2 13 (50.0%) 34 (28.8%)
3 1 (3.8%) 6 (5.1%)
4 1 (3.8%) 0 (0.0%)
Unknown 0 12
Lymph node status
N0 11 (44.0%) 53 (55.2%) 1.53 (0.65–3.61) P¼0.332
N1 10 (40.0%) 30 (31.3%)
N2 3 (12.0%) 10 (10.4%)
N3 1 (4.0%) 3 (3.1%)
Unknown 1 34
Oestrogen receptor status
Positive (10–100%) 12 (46.2%) 91 (79.1%) 0.21 (0.07–0.53) P¼0.001
Negative (0–10%) 14 (53.8%) 24 (20.9%)
Unknown 0 15
Progesterone receptor status
Positive (10–100%) 9 (34.6%) 90 (78.3%) 0.10 (0.03–0.29) Po0.001
Negative (0–10%) 17 (65.4%) 25 (21.7%)
Unknown 0 15
HER2 amplification
Yes 8 (30.8%) 11 (9.6%) 5.46 (1.67–20.11) P¼0.006
No 18 (69.2%) 104 (90.4%)
Unknown 0 15
Triple-negative
Yes 5 (19.2%) 15 (13.0%) 1.65 (0.48–5.09) P¼0.399
No 21 (80.8%) 100 (87.0%)
Unknown 0 15
Ki-67 status
Mean (s.d.) 33.3% (22.8) 29.3% (22.5) P¼0.334
Unknown 0 15
Abbreviations: CI¼ confidence interval; HER2¼ human epidermal growth factor receptor 2; NF1¼ neurofibromatosis 1; OR¼odds ratio.
aPercentage calculated for cases with known status only.
bOdds ratios and 95% CIs are derived from generalised mixed effects models with NF1 diagnosis as the exposure variable, and a grouping variable that indexes matched sets as a random
effect. Therefore, ORs illustrate the odds of NF1 patients compared with controls for each outcome.






























Figure 1. Survival of NF1 breast cancer patients and age, year of the
diagnosis, sex and oestrogen receptor status (þ / ) -matched
control breast cancer patients, P¼0.053. Numbers of NF1 patients
and controls at risk are shown below the figure.
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NF1. Thus, some effects may be unspecific and because of copy
number alterations of BRCA1 or other nearby genes. However,
restricting the analysis to NF1 mutations showed similar pattern in
terms of survival and receptor status. The concordance between
breast cancers of NF1 patients and TCGA breast tumours with NF1
mutations or deletions, or mutations only, suggests that these
effects may be associated with the NF1 gene.
Breast cancer of young women is generally associated with a
worse prognosis and a higher incidence of unfavourable clinico-
pathological features (Adami et al, 1986; Nixon et al, 1994; Anders
et al, 2008; Sheridan et al, 2014) than of older women. These
features include lack of ER, larger tumour size, more frequent
HER2 amplifications, wider local spread to lymph nodes, higher
tumour grade and a trend towards poorer disease-free survival
(Anders et al, 2008). Because young patients were overrepresented
in the NF1 group in our study, we also expected to find these
characteristics in NF1 breast cancers. However, it was surprising to
note that breast cancers of NF1 patients were even more often
associated with unfavourable prognostic factors, such as ER and PR
loss and HER2 amplification, than breast cancers of age- and sex-
matched controls. The proportion of HER2 subtype in breast
cancers in women o50 years has been reported to be 12%
(Sihto et al, 2008), but in our study it was 33% (4 out of 12).
However, these characteristics alone do not explain the poor
survival of the NF1 patients with breast cancer.
The poor prognosis of NF1 breast cancer patients may also
partly be because of advanced stage at the time of diagnosis. The
breast cancers of the NF1 patients were larger and of higher grade
at the time of surgery, although the slightly worse lymph node
status of NF1 patients was not statistically significant. It has been
speculated that subcutaneous neurofibromas may interfere with the
clinical diagnostic workup of breast cancer (Evans, 2012; Da Silva
et al, 2015) and this might cause a delay in NF1 breast cancer
diagnosis. However, the results of the present study show that
diagnostic delay of NF1-related breast cancer – if present – does
not explain the characteristics of NF1 breast cancers. The TCGA
breast cancers are independent of NF1 disease manifestations, but
they still show an association between poor survival, unfavourable
prognostic factors and NF1 mutations/deletions.
The mechanism by which loss of NF1 function is associated
with a poor outcome of breast cancer patients is probably caused
by uninhibited Ras signalling via the PI3K and Raf/MAPK/ERK
pathways. Increased PI3K activity has often been related to poor
survival and resistance to hormone treatment in ER-negative
breast cancer (Yang et al, 2016), whereas elevated Ras/MAPK/
ERK activity has been related to metastasis and poor survival in
both ER-positive luminal (Wright et al, 2015) and ER-negative
breast cancer (Giltnane and Balko, 2014). In the absence of
inhibition by NF1, enhanced and prolonged Ras stimulation by
cell membrane tyrosine kinase receptors such as EGFR and
HER2 can activate, via the Raf/MAPK/ERK pathway, several
transcription factors, such as c-myc and ETS1. These pathways
and factors are involved in stimulation of cell proliferation,
viability, epithelial–mesenchymal transition, migration and
invasion (Giltnane and Balko, 2014), the effects of which may
strongly facilitate breast cancer development and progression in
NF1 patients (Rad and Tee, 2016).
Although the material is unique, the number of archival samples
was relatively small (n¼ 26) to make definitive conclusions in
cancer that has five subgroups. However, the differences in
distribution of receptors statuses were statistically highly signifi-
cant. The survival analysis is based on all-cause mortality, as the
causes of death were not available for the controls. However, 7 of
the 8 NF1 patients who died during the 5-year period used in the
survival analysis had breast cancer as the cause of death and no
other comorbidities contributing to the death recorded in the death
certificates.
The results of the current study highlight the question of the
surveillance strategy for NF1 breast cancer. Tung et al (2016) have
suggested intensified monitoring by mammography for carriers of
breast cancer predisposing gene variants at the age when the risk
exceeds that of the general population being routinely screened.
For NF1 patients, this would mean the age group of 30–39 years
where the risk is 4.7% (Table 2). However, more evidence is needed
on the effectiveness and safety of different screening methods in
NF1 patients. Further prospective international effort is called for
the elucidation of recommendations for intensified follow-up of
breast cancer in NF1 patients. Currently, we suggest the following:
(1) increasing the awareness of NF1 patients and their doctors of
the high breast cancer risk especially in young women with NF1,
(2) yearly clinical follow-up since young adulthood by doctor
familiar with NF1 syndrome, and (3) any suspicion of breast
cancer should warrant imaging.
Our results suggest that NF1mutations are an independent factor
contributing to poor survival of patients with breast cancer.
We conclude that the awareness of the strong association between
breast cancer and NF1 should affect breast cancer research in
general, as NF1 also seems to be a modifier of the clinical char-
acteristics of breast cancer in the general population without NF1.
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